

HELP PROTECT TRAVELLERS

ViVAXIM® offers dual protection against hepatitis A and typhoid fever in a single shot.¹

WHERE ARE TRAVELLERS AT GREATEST RISK?

Hepatitis A and typhoid fever share a number of risk areas overseas, making combined vaccination with ViVAXIM® a convenient option for travellers to: Asia (except Japan), Africa, the Caribbean, and Central and South America.^{2,3}

Travellers to these popular destinations are at risk of contracting hepatitis A and typhoid fever. In endemic areas, these common diseases are **transmitted through contaminated food and drink.**^{4,5}

Talk to your patients about safe food and drink consumption abroad, and discuss vaccination options at least two weeks before departure.

WHO CAN BE VACCINATED WITH ViVAXIM®?

ViVAXIM® is indicated for persons 16 years and older, and should be given at least 14 days before risk of exposure to both hepatitis A and typhoid fever.¹

ViVAXIM® is indicated for simultaneous active immunization against infection caused by *S. typhi* (the organism that causes typhoid fever), and hepatitis A virus, in persons 16 years of age or older. ViVAXIM® can be used for hepatitis A primary immunization or booster, and for typhoid primary immunization or revaccination.

Consult the product monograph at products.sanofi.ca/en/vivaxim.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-888-621-1146.

For more information, visit www.sanofi.ca.



DID YOU KNOW?

Hepatitis B vaccination is offered as part of public immunization programs, while hepatitis A and typhoid fever are NOT INCLUDED in Canadian routine vaccine schedules (except in Quebec, where hepatitis A vaccine is offered in grade 4).⁶

ViVAXIM® is a logical choice for travellers, as it offers dual protection against hepatitis A and typhoid fever.¹



1 DOSE helps protect against **2 DISEASES.**
3-YEAR interval until re-immunization dose (if risk of infection persists).¹

REFERENCES: 1. Sanofi Pasteur Limited, ViVAXIM Product Monograph. 2015. 2. Government of Canada, Travel Health and Safety: Typhoid Fever. 2016. 3. Government of Canada, Travel Health and Safety: Risks of Hepatitis A. 2019. 4. Centers for Disease Control and Prevention (CDC), *Hepatitis A*. 2019. 5. CDC, *Typhoid Fever*. 2013. 6. Government of Canada, Canada's Provincial and Territorial Routine (and Catch-up) Vaccination Routine Schedule Programs for Infants and Children. 2019.

ViVAXIM® is a registered trademark of Sanofi Pasteur. © 2019 Sanofi Pasteur Limited. All rights reserved. SPCA.VIVAX.19.05.0016 E

